guide
How telehealth peptide therapy actually works
A step-by-step look at how a licensed telehealth practice moves from medical intake to physician review to a compounded prescription, using Live Vital's process as the example.
ReadBlog
Physician-reviewed guides on peptide therapy, weight loss, and longevity. Clear, clinical, and written for people deciding whether treatment is right for them.
Guides
Research
- research
How semaglutide and tirzepatide are changing bariatric surgery patterns
A study in Surgical Endoscopy used a nationwide health records database to track how bariatric surgery use and pre-surgery GLP-1 medication use shifted between 2018 and 2025. It found surgery volumes dropped after 2022 while more surgery patients had taken a GLP-1 first, with clear differences by race, insurance, and hospital.
Read - research
What a European Heart Journal review says about medical therapy for peripheral artery disease
A 2024-era review in European Heart Journal summarizes current drug and lifestyle strategies for peripheral artery disease and notes emerging data on GLP-1 receptor agonists. It is a synthesis of existing evidence, not a new trial, and it describes treatment categories rather than promising results for any individual.
Read - research
What a real-world study found comparing semaglutide and liraglutide
A claims-based study emulating a clinical trial found that adults without diabetes or cardiovascular disease who used semaglutide had a lower one-year risk of developing diabetes than those who used liraglutide, with no detectable difference in cardiovascular events. The findings are observational and cannot prove cause and effect.
Read
News & Commentary
- commentary
What the telehealth GLP-1 oversight story actually says
A Healthcare Brew report flags that some telehealth GLP-1 prescriptions come with thin clinician oversight and light regulation. Here is what that reporting establishes, what it does not, and what it means if you are considering legitimate physician-prescribed care.
Read - commentary
Injectable Peptides for Patients: A Physician's Guide
Dr. Taylor cuts through the noise on injectable peptides — what the evidence actually supports, who qualifies, and how to stay safe. A clinically grounded patient guide.
Read - commentary
Tirzepatide vs Semaglutide Weight Loss: What the New Data Means
Dr. Taylor breaks down the latest real-world tirzepatide vs semaglutide weight loss study and what it means for your treatment decision. Telehealth consult available.
Read - commentary
Injectable Peptides for Patients: What You Need to Know
Dr. Taylor breaks down this week's peptide therapy news, helping patients separate clinical evidence from hype before their next telehealth visit.
Read - commentary
Tirzepatide vs Semaglutide Weight Loss: What's Better?
Dr. Taylor breaks down new real-world data on tirzepatide vs semaglutide weight loss — and what it means for patients deciding between these two medications.
Read - commentary
Peptide Therapy Reclassification 2025: What It Means for You
Dr. Taylor cuts through the political noise on peptide therapy reclassification 2025, explaining real clinical and access implications for current and new patients.
Read - commentary
BPC-157 Peptide Therapy Safety: A Physician's View
Dr. Taylor cuts through the social media hype on BPC-157 peptide therapy safety, giving patients an honest risk-benefit framework grounded in real clinical evidence.
Read - commentary
Injectable Peptides for Patients: A Physician's Guide
Dr. Taylor cuts through the noise on peptide therapy. Get a clinically grounded framework to decide if injectable peptides are right for your health goals.
Read - commentary
Stopping Semaglutide After Weight Loss: What to Know
Dr. Taylor explains the latest evidence on GLP-1 de-escalation vs. lifelong use, so patients can make informed decisions about stopping semaglutide after weight loss.
Read - commentary
Compounded Semaglutide FDA Deadline: Your Action Plan
Dr. Taylor explains what the FDA's compounded semaglutide deadline means for telehealth patients and how to protect your access before the window closes.
Read - commentary
Compounded Semaglutide FDA Ban: What Patients Need to Know
Dr. Taylor breaks down the FDA's compounded semaglutide ban, what it means for telehealth GLP-1 patients, and how to protect your treatment plan going forward.
Read - commentary
Peptide Therapy Access 2026: What Patients Must Know
Dr. Taylor cuts through the 2026 regulatory noise to explain which peptides are at risk, which are newly legitimized, and what you should do right now.
Read - commentary
Peptide Therapy Side Effects: A Physician's Honest Guide
Dr. Taylor cuts through social media hype to give patients an evidence-based framework for evaluating peptide therapy side effects, safety, and FDA regulatory shifts.
Read - commentary
Why GLP-1 Not Working? Genetics May Explain It
Dr. Taylor unpacks new genetic and pharmacological research to help patients understand why GLP-1 response varies — and what to do before giving up on therapy.
Read
Spotlight
- spotlight
How to bring up peptides with a physician
A practical guide to preparing for a conversation about physician-prescribed peptide therapy, including what these compounds are and how care is accessed through a medical intake and physician review.
Read - spotlight
How to evaluate peptide information before you start care
A practical guide to telling credible peptide information from noise, and how physician-prescribed treatment actually works through a medical intake and review.
Read - spotlight
Testosterone replacement formats and what to know before starting
A plain look at the different delivery formats for physician-prescribed testosterone therapy, and how legitimate access begins with a medical intake and physician review rather than a retail purchase.
Read - spotlight
What to know about gut-focused peptides before you start
An experimental gut-lining peptide called larazotide acetate has renewed interest in whether peptides can support the intestinal barrier. Here is how physician-reviewed peptide care actually works, and what to sort out before anything is prescribed.
Read - spotlight
Why peptides and steroids are not the same thing
Peptides and anabolic steroids are different classes of molecules that work through different mechanisms, and this piece explains that distinction for readers considering legal, physician-prescribed peptide care through telehealth.
Read
Peptides & HRT
- commentary
Your Apple Watch flagged possible sleep apnea. Here is what to do next
A wearable notification about breathing disturbances is a prompt, not a diagnosis. This piece explains how to interpret it, what confirming a diagnosis actually involves, and where physician-reviewed care fits.
Read - roundup
How telehealth widens access to physician-prescribed care
A practical look at how a nationwide telehealth practice reviews and prescribes care through a medical intake, and what to know before you start.
Read - commentary
GLP-1 medications and fertility questions worth asking your physician
An overview of how GLP-1 receptor agonists intersect with metabolic health and fertility conversations for women with obesity or insulin resistance, and how physician-prescribed care is accessed through a medical intake.
Read - roundup
How to evaluate a physician-prescribed telehealth service
A practical guide for readers weighing direct-to-consumer prescription brands, focused on what physician review and a real medical intake actually mean.
Read - commentary
Microdosing GLP-1s and what the term actually means
A plain look at what people mean by microdosing GLP-1 medications, why dosing is a clinical decision, and how physician-prescribed GLP-1 care is accessed through a medical intake at Live Vital.
Read - commentary
Restarting a GLP-1 medication after time off
Coming back to a GLP-1 after months away, including after pregnancy, is a medical decision that a physician makes at re-intake. Here is how the restart conversation actually works and why past dosing rarely maps onto a new start.
Read - commentary
What to actually look for when you research compounded tirzepatide
A physician-led look at how compounded GLP-1 medications work through licensed telehealth, why price-shopping vendors is the wrong first step, and what it may mean when a current medication is not producing the response you expected.
Read - roundup
What to know about LL-37 and physician-prescribed peptide care
LL-37 is an antimicrobial peptide drawing growing interest in the telehealth space. Here is how prescription peptide care actually works, from medical intake to physician review, and what to consider before you start.
Read
Ready to start?
Every protocol at Live Vital is physician-prescribed after a medical intake and physician approval. Outcomes vary by individual.